DAMORA THERAPEUTICS, INC. Increase (Decrease) in Accounts Payable
DAMORA THERAPEUTICS, INC. (DMRA) reported Increase (Decrease) in Accounts Payable of $3.04 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-10
- DAMORA THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $2.66M, a 562.44% increase year-over-year.
- DAMORA THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $375.00K.
- DAMORA THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$92.00K.
- DAMORA THERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$236.00K.
- DAMORA THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2025 was $51.00K.
- DAMORA THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2024 was -$1.32M.
- DAMORA THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2023 was -$1.65M, a 190.60% decline from fiscal 2022.
- DAMORA THERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2022 was $1.82M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $3.04M 10-Q · filed 2026-08-10 | $2.95M derived: sum of 3 quarters · filed 2026-08-10 | $2.71M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $375.00K 10-Q · filed 2026-05-12 | $283.00K derived: sum of 2 quarters · filed 2026-05-12 | $47.00K derived: sum of 3 quarters · filed 2026-05-12 | $449.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$92.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$328.00K derived: sum of 2 quarters · filed 2026-03-19 | $74.00K derived: sum of 3 quarters · filed 2026-08-10 | $51.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | -$236.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $166.00K derived: sum of 2 quarters · filed 2026-08-10 | $143.00K 10-Q · filed 2025-11-06 | $17.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $402.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $379.00K 10-Q · filed 2026-08-10 | $253.00K derived: sum of 3 quarters · filed 2026-08-10 | $32.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$23.00K 10-Q · filed 2026-05-12 | -$149.00K derived: sum of 2 quarters · filed 2026-05-12 | -$370.00K derived: sum of 3 quarters · filed 2026-05-12 | -$1.31M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$126.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$347.00K derived: sum of 2 quarters · filed 2026-03-19 | -$1.29M derived: sum of 3 quarters · filed 2026-03-19 | -$1.32M 10-K · filed 2026-03-19 |
| 2024-09-30 | -$221.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.16M derived: sum of 2 quarters · filed 2025-11-06 | -$1.20M 10-Q · filed 2025-11-06 | -$3.97M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$941.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$978.00K 10-Q · filed 2025-08-05 | -$3.75M derived: sum of 3 quarters · filed 2025-08-05 | -$4.83M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | -$37.00K 10-Q · filed 2025-05-08 | -$2.81M derived: sum of 2 quarters · filed 2025-05-08 | -$3.89M derived: sum of 3 quarters · filed 2025-05-08 | -$1.89M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$2.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | -$3.85M derived: sum of 2 quarters · filed 2025-03-19 | -$1.85M derived: sum of 3 quarters · filed 2025-03-19 | -$1.65M 10-K · filed 2025-03-19 |
| 2023-09-30 | -$1.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-01 | $927.00K derived: sum of 2 quarters · filed 2024-11-01 | $1.13M 10-Q · filed 2024-11-01 | $2.57M derived: sum of 4 quarters · filed 2024-11-01 |
| 2023-06-30 | $2.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $2.21M 10-Q · filed 2024-08-12 | $3.65M derived: sum of 3 quarters · filed 2024-08-12 | $2.74M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $200.00K 10-Q · filed 2024-04-29 | $1.64M derived: sum of 2 quarters · filed 2024-04-29 | $735.00K derived: sum of 3 quarters · filed 2024-04-29 | $335.00K derived: sum of 4 quarters · filed 2024-04-29 |
| 2022-12-31 | $1.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $535.00K derived: sum of 2 quarters · filed 2024-03-08 | $135.00K derived: sum of 3 quarters · filed 2024-03-08 | $1.82M 10-K · filed 2024-03-08 |
| 2022-09-30 | -$908.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$1.31M derived: sum of 2 quarters · filed 2023-11-06 | $376.00K 10-Q · filed 2023-11-06 | -$73.00K derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | -$400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-31 | $1.28M 10-Q · filed 2023-07-31 | $835.00K derived: sum of 3 quarters · filed 2023-07-31 | $1.23M derived: sum of 4 quarters · filed 2023-07-31 |
| 2022-03-31 | $1.68M 10-Q · filed 2023-04-28 | $1.24M derived: sum of 2 quarters · filed 2023-04-28 | $1.63M derived: sum of 3 quarters · filed 2023-04-28 | $1.43M derived: sum of 4 quarters · filed 2023-04-28 |
| 2021-12-31 | -$449.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$54.00K derived: sum of 2 quarters · filed 2023-03-09 | -$251.00K derived: sum of 3 quarters · filed 2023-03-09 | -$1.32M 10-K · filed 2023-03-09 |
| 2021-09-30 | $395.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $198.00K derived: sum of 2 quarters · filed 2022-11-08 | -$871.00K 10-Q · filed 2022-11-08 | -$2.48M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$197.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-29 | -$1.27M 10-Q · filed 2022-07-29 | -$2.88M derived: sum of 3 quarters · filed 2022-07-29 | -$162.00K derived: sum of 4 quarters · filed 2022-07-29 |
| 2021-03-31 | -$1.07M 10-Q · filed 2022-04-29 | -$2.68M derived: sum of 2 quarters · filed 2022-04-29 | $35.00K derived: sum of 3 quarters · filed 2022-04-29 | $171.00K derived: sum of 4 quarters · filed 2022-04-29 |
| 2020-12-31 | -$1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $1.10M derived: sum of 2 quarters · filed 2022-02-17 | $1.24M derived: sum of 3 quarters · filed 2022-02-17 | -$477.00K 10-K · filed 2022-02-17 |
| 2020-09-30 | $2.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $2.85M derived: sum of 2 quarters · filed 2021-11-04 | $1.13M 10-Q · filed 2021-11-04 | $3.83M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $136.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$1.58M 10-Q · filed 2021-08-05 | $1.12M derived: sum of 3 quarters · filed 2021-08-05 | |
| 2020-03-31 | -$1.72M 10-Q · filed 2021-05-04 | $983.00K derived: sum of 2 quarters · filed 2021-05-04 | ||
| 2019-12-31 | $2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $1.94M 10-K · filed 2021-03-29 | ||
| 2019-09-30 | -$762.00K 10-Q · filed 2020-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |